[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-373976-105":59,"doc-detail-373976-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","from-lab-to-lifesaver-the-rise-of-cart-cell-therapy-in-oncology","From lab to lifesaver: the rise of CART-cell therapy in oncology","","Cancer care is undergoing a major shift driven by immunotherapies, especially chimeric antigen receptor (CAR) T-cell therapy. Despite its strong and often revolutionary benefits in hematologic malignancies, persistent barriers remain, including severe toxicities, high treatment costs, and limited effectiveness in solid tumors. This review synthesizes current advances, emphasizing how CAR design enables antigen recognition, triggers intracellular signaling, supports cytotoxic activity, and outlines clinical applications alongside major obstacles and emerging innovations toward safer, more effective patient-specific strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-lab-to-lifesaver-the-rise-of-cart-cell-therapy-in-oncology/373976/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-lab-to-lifesaver-the-rise-of-cart-cell-therapy-in-oncology/373976.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What challenges limit CAR T-cell therapy in cancer treatment?","Question",{"text":112,"@type":113},"Severe toxicities, high treatment costs, and limited efficacy in solid tumors constrain outcomes. The review also highlights ongoing barriers that require continued innovation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CAR T-cell therapy recognize and attack cancer cells?",{"text":117,"@type":113},"CAR proteins present an antigen recognition domain that binds tumor antigens and intracellular signaling domains that activate cytotoxic functions. This enables T cells to interact with cancer cells and mount an anticancer response.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety risks are discussed for CART-cell therapy?",{"text":121,"@type":113},"The review identifies cytokine release syndrome (CRS) and neurotoxicity as key obstacles. It also addresses antigen escape mechanisms that can reduce effectiveness.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},373976,1790226798,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Jangavali et al.  \nJournal of the Egyptian National Cancer Institute (2025) 37:37  \n[https://doi.org/10.1186/s43046-025-00262-6](https://doi.org/10.1186/s43046-025-00262-6)  \nJournal of the Egyptian National Cancer Institute  \n REVIEW Open Access  \nFrom lab to lifesaver: the rise of CART-cell therapy in oncology  \nShriyash S. Jangavali 1, Pallavi B. Hangargekar2* , Balasaheb U. Gangthade 1, Shreya A. Jadhav 1, Ujwal A. Havelikar3 and Amol A. Joshi4  \nAbstract  \nBackground Recently, cancer treatment paradigms have shifted dramatically with the advent of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapy. Despite it is revolutionary positive outcomes in treating hematologic malignancies, challenges such as severe toxicities, high treatment costs, and limited efficacy in solid tumors persist. This review highlights these limitations and the ongoing need for innovation in CART-cell therapy. Main body This manuscript provides a comprehensive review of most current advancements in CART-cell therapy, with a focus on targeting its immunotherapeutic principles, modification ofT cells for Targeted cancer therapy using T cells, and clinical applications. It explores the key elements of CART-cell therapy, containing antigen recognition domain and intracellular signaling domains, which enable T cells to interact with cancer cells and exert cytotoxic effects. The review examines approved therapies, and ongoing clinical trials, Along with obstacles like cytokine release syndrome (CRS), neurotoxicity, along antigen escape mechanisms. Furthermore, innovations in cutting-edge CART-cell therapies and personalized treatment approaches are discussed, together with an emphasis on improving safety and efficacy.  \nConclusion The manuscript outlines the future outlook on integrating CART-cell therapy integrated with other treatments and exploring patient-specific approaches to revolutionize cancer care. This review aims to bridge the existing gaps in research, offering valuable insights for students and researchers in biomedical sciences and oncology. Keywords Chimeric antigen receptor, Oncology, Cancer immunotherapy, Cytotoxic release syndrome, CART-cell therapy  \nIntroduction  \nWith rising yearly incidence and fatality rates, cancer poses a serious health risk [1]. The cornerstone of cancer treatment for many years has involved the combination  \n*Correspondence: Pallavi B. Hangargekar [pallavibh10@gmail.com](pallavibh10@gmail.com)  \n1 Department of Pharmacy, ASPM’s K. T. Patil College of Pharmacy, Dharashiv 413501, Maharashtra, India  \n2 Department of Quality Assurance, ASPM’s K. T. Patil College of Pharmacy, Dharashiv 413501, Maharashtra, India  \n3 Department of Pharmacy, NIMS Institute of Pharmacy, Jaipur, Rajasthan, India  \n4 Department of Pharmacognosy, ASPM’s K. T. Patil College of Pharmacy, Dharashiv 413501, Maharashtra, India  \nof newly evolved targeted medicines As well as conventional therapies as in the case of radiation, surgical intervention, and chemotherapy. Although they have shown promise, several cancers have poor prognoses that have been linked to treatment for associated consequences [2]. The therapeutic view of human cancers has evolved within the past ten years with the introduction of various innovative therapeutic strategies. The application of immunotherapy has revolutionized the field of cancer treatments [3]. One highly successful cellular immunotherapy approach for cancer treatment involves the engineering of immune cells for the production of cell surface receptors that might recognize and remove antigens found on the surface of tumor cells [1]. Successfully  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons lice","cbCaikw2QAz3ms86","https://ap.wps.com/l/cbCaikw2QAz3ms86","pdf",1403811,15,"English","# Abstract\n# Background\n# Main body\n## Key elements of CAR T-cell therapy\n## Clinical applications and approved therapies\n## Challenges and toxicities\n## Innovations and personalized approaches\n# Conclusion","[{\"question\":\"What challenges limit CAR T-cell therapy in cancer treatment?\",\"answer\":\"Severe toxicities, high treatment costs, and limited efficacy in solid tumors constrain outcomes. The review also highlights ongoing barriers that require continued innovation.\"},{\"question\":\"How does CAR T-cell therapy recognize and attack cancer cells?\",\"answer\":\"CAR proteins present an antigen recognition domain that binds tumor antigens and intracellular signaling domains that activate cytotoxic functions. This enables T cells to interact with cancer cells and mount an anticancer response.\"},{\"question\":\"What safety risks are discussed for CART-cell therapy?\",\"answer\":\"The review identifies cytokine release syndrome (CRS) and neurotoxicity as key obstacles. It also addresses antigen escape mechanisms that can reduce effectiveness.\"}]","From lab to lifesaver: the rise of CART-cell therapy in oncology | PDF",1790200933,38]